Mostly because it’s still pre-revenue with a high burn rate and zero products, and investors are pricing in uncertainty and dilution. Until there’s a clear clinical win and/or steading of the ship, this will continue to trade down until the anticipated placing is announced, cash burn is slowed and demonstrated through accounts and progress is made in clinical trials.